geron corporationpure price action , i see this asset making the last push to the down before going higher
0IV3 trade ideas
Long GERN @4.43 Oversold in a strong recent uptrend. Will hold each lot until it is both overbought AND profitable. No stops for me. Had a dizzying 40% drawdown back in September '23 and held 14 lots at the bottom of that.
In the end, though, all 14 (and the next 13) turned a profit. The indicator and exit strategy combo is 27-0 (with two recently opened positions) in the last 12M. Average gain per trade is 12.9% and median trade was +10.0%. B/H for GERN was +42% in the last 12M while the equal dollar trades produced a cumulative +347% over the same time.
I will try to update added positions or if I close positions.
GERN - PDUFA Data Release on 16/06/2024Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
Recent Activity
Blockbuys: See the screenshot in the chart.
Expecting: A pre run-up into the data release on 16/06/2024.
Key Technical Levels
Breakout Zone: $3.70 - $4.00 (Very strong resistance)
Resistance Points:
$4.30
$4.60
Surpassing these levels could signal a positive trend. Consider taking profits at these stages to realize gains.
Trading Strategy
Take Profit (TP): Target $5.00 to capitalize on the anticipated price gap closure (this likely only works if the data release is positive).
Stop Loss (SL): Set at under $3.50 to mitigate potential losses.
Chart Analysis
Please refer to the attached chart for detailed analysis of price trends and movements.
Trading Advisory
Exercise caution and consider market conditions and your own risk tolerance when trading. Conduct comprehensive research or consult with a financial advisor before engaging in trading activities.
Disclaimer
This content is for informational purposes only and should not be considered financial advice.
GERON Corporation Bullish momentum
Title:
GERON Corporation: Bullish Momentum
Overview:
🌟 Hello Traders,
GERON Corporation is currently exhibiting bullish momentum, indicating potential opportunities for traders in the market.
NASDAQ:GERN
Key Points:
- GERON Corporation is experiencing strong bullish momentum, with positive price action and increasing investor interest.
- The company's stock price has been on an upward trend, supported by favorable news and market sentiment.
- Traders are closely monitoring GERON Corporation for potential entry points and opportunities to capitalize on the bullish momentum.
Technical Analysis:
GERN's price chart reflects a bullish pattern, with the stock consistently making higher highs and higher lows. Technical indicators support the bullish bias, suggesting further upside potential.
Conclusion:
With GERON Corporation demonstrating strong bullish momentum, traders may consider exploring long opportunities in the market. However, it's essential to conduct thorough research and practice risk management strategies to mitigate potential losses.
Don't Forget to Engage:
🟢 Please LIKE 🟡 FOLLOW 🔵 SHARE &
🔴 COMMENT
If you found this idea insightful! Your engagement contributes to the community's knowledge and helps broaden the reach of valuable insights.
Leave your feedback in the comment section below or by boosting /Liking this.
See you in the next idea post.
Happy trading!
Geron's Imetelstat Receives FDA Advisors' BackingGeron Corporation's ( NASDAQ:GERN ) blood disorder drug, Imetelstat, has received a crucial vote of confidence from advisers to the U.S. Food and Drug Administration (FDA). Despite initial concerns raised by the agency's staff regarding data clarity and safety issues, the advisory panel overwhelmingly backed the benefits of Imetelstat for treating transfusion-dependent anemia in patients with myelodysplastic syndromes (MDS), a group of blood cancers.
The panel's resounding endorsement of Imetelstat, by a wide 12-to-2 margin, underscores the drug's potential to address an unmet medical need in a patient population with limited treatment options. While acknowledging the associated risks and toxicities of the treatment, panelists emphasized that these appear to be manageable, particularly in the context of the severity of MDS and the scarcity of effective therapies.
Geron's pursuit of FDA approval for Imetelstat represents a significant milestone for the company, marking its potential entry into the commercial treatment market. If approved, Imetelstat will compete with Bristol Myers Squibb's Reblozyl, which received FDA approval last year for the same disease indication. Analysts project substantial market opportunity for Imetelstat, with estimates suggesting potential sales of $933 million by 2029, underscoring the drug's commercial potential and the sizable unmet need it aims to address.
Despite concerns raised by the FDA regarding the lack of additional benefits beyond the primary study goal of increasing transfusion independence, Geron ( NASDAQ:GERN ) remains optimistic about Imetelstat's prospects. The company asserts that transfusion independence serves as the regulatory gold standard for approvals in this patient setting, highlighting the significance of achieving this milestone in the drug's development.
The panel's endorsement of Imetelstat represents a significant step forward in the quest to advance treatment options for patients with MDS-related anemia. With the potential to provide a much-needed therapeutic option for a vulnerable patient population, Imetelstat stands poised to make a meaningful impact in the field of hematology, offering hope to patients and caregivers alike.
As Geron awaits the FDA's final decision on Imetelstat, the company remains committed to advancing the development of innovative therapies to address critical unmet needs in hematologic disorders. With Imetelstat on the cusp of potential approval, Geron looks forward to realizing its mission of transforming the treatment landscape for patients battling blood disorders.
GERON Stock Chart Fibonacci Analysis 022724Trading Idea
1) Find a FIBO slingshot
2) Check FIBO 61.80% level
3) Entry Point > 2.2/61.80%
Chart time frame : B
A) 15 min(1W-3M)
B) 1 hr(3M-6M)
C) 4 hr(6M-1year)
D) 1 day(1-3years)
Stock progress : B
A) Keep rising over 61.80% resistance
B) 61.80% resistance
C) Hit the bottom
D) Hit the top
Stocks rise as they rise from support and fall from resistance. Our goal is to find a low support point and enter. It can be referred to as buying at the pullback point. The pullback point can be found with a Fibonacci extension of 61.80%. This is a step to find entry level. 1) Find a triangle (Fibonacci Speed Fan Line) that connects the high (resistance) and low (support) points of the stock in progress, where it is continuously expressed as a Slingshot, 2) and create a Fibonacci extension level for the first rising wave from the start point of slingshot pattern.
When the current price goes over 61.80% level , that can be a good entry point, especially if the SMA 100 and 200 curves are gathered together at 61.80%, it is a very good entry point.
As a great help, tradingview provide these Fibonacci speed fan lines and extension levels with ease. So if you use the Fibonacci fan line, the extension level, and the SMA 100/200 curve well, you can find an entry point for the stock market. At least you have to enter at this low point to avoid trading failure, and if you are skilled at entering this low point, with fibonacci6180 technique, your reading skill to chart will be greatly improved.
If you want to do day trading, please set the time frame to 5 minutes or 15 minutes, and you will see many of the low point of rising stocks.
If want to prefer long term range trading, you can set the time frame to 1 hr or 1 day.
GERN - long - Catalyst playGeron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug. the company operates as a single segment, the development of therapeutic products for oncology.
This is not a financial advice!
Recent block buys
Upcoming catalyst on 14th of March
Keep an eye on 2.35 level - needs to get broken for a further upmove.
SL under 1.9
TP approx. 3.0
Most info on the chart.
Trade carefully!
gern buy idea with stop shown in the graphgern buy idea with stop shown in the graph
we must keep the stop as shown in the graph
BUY GERON CORP. (GERN)Shares of Geron have been on the retail trader’s radar following a series of news and industry catalysts. The late-stage biopharmaceutical company specializes in developing treatments for hematologic malignancies. At the beginning of the year, the company announced positive top-line results from its IMerge Phase 3 trials of imetelstat.
t’s the company’s candidate in targeting such hematologic malignancies and, in this case, showed a response in patients with lower-risk myelodysplastic syndromes. The trial met its primary endpoint for efficacy and showed “statistically significant and clinically meaningful” benefits versus placebo. It also released headlines showing that the company plans on hiring a senior leadership team specifically focused on the commercial launch of imetelstat in the U.S.
What do analysts think about GERN stock? If you look at the rating from B. Riley, you’ll see it has Geron set with a Buy rating and a $5 target. Based on recent closing prices of $3.40, that’s 47% higher at the moment.
Buy with the target price above 5.5 and keep stop loss at 2.9 and trade according..as this is peeny stocks there is high probability of profit and losses..so trade accordingly to your risk and rewards,
Thankyou if you like my idea then please like and follow me on tradingview.com
GERN: Daily VCPSetup: Rocketbase
VCP: 5W 39/6 4T
RS: 98
The posted chart contains a VCP (volatility contraction pattern). The first label "W" stands for weekly and shows the duration of the entire consolidation. In the middle label, the percentage of contractions is indicated (for example, "15/4"), with 15 representing the -15% depth of the base and 4 representing -4% of the last contraction. The last part "T" represents the number of contractions. The light blue lines in the chart correspond to the contractions. A more detailed description can be found in Mark Minervini's books.
RS stands for relative strength and measures the strength of the stock compared to the overall market. The value range is 1-99 with 99 being the highest value. The rank was generated by fyntrade.
GERN for a swingshort term resistance seen but the daily support is very good. so a bounce from daily support should take it to the 5$ mark
GERN Biotechology Penny Stock impending EarningsNASDAQ:GERN
Chart showing good uptrend with average directional index
and sitting above the cloud,
GERN had a micro pullback on Friday and so is now
ready for an entry.
Resistance @ 3.20 back in 2019; Potential upside 35% or more.
$2.5 Strike Expiring 8/19.
Geron Corporation in recovery. GERNB or X Wave. Recovery within a recovery.
This is a reflection using technical analysis + only and we do not consider valuation and macro factors at this stage.
The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe!
GERN - DIAMOND TOP/BOTTOM - BULLISH MOVEAll, this chart sucks in all honestly, but think we are looking at a reversal here, needs to hold exact level it's at before moving up or may drop down one level bounce and should break out the top. Either way WW this week/next.
Assuming bullish news at conference If we see good news from the upcoming presentation GERN is giving, we can expect a boost all the way to old highs.
GERN LongSupport line
Entry 1.65
Stop 1.25
Target 3.3
I am not a PRO trader. I trade option to test my trading plan with small cost.
The max Risk of each plan is less than 1% of my account.
If you like this idea, please use SIM/Demo account to try it.
Long | GERNNASDAQ:GERN
Possible Scenario: LONG
Evidence: Price Action
This is my idea and could be wrong 100%
* It's a good buy opportunity right now, and it's ready to fly soon.
$GERN for sale next week!Bought this yesterday with the following reasons:
1. Stoch RSI at oversold level
2. Fibo and extended fibo retracement levels are followed
3. Realistic target prices
4. Tolerable cutloss level
Bought at 2, targetting 2.36 in two trading days! If it breaks 2.36 next week, I guess this stock will ride a rocket. Newbie trader here :)
GERN - looks like it's breaking outThis one has a nice impulse up and it starting to look like it will continue that move. Once breaking out of the larger degree structure it looks like some positive buying is happening now.
GERN - long - possible wedge breakoutGeron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.
